BeOne Medicines presents BRUKINSA 78-month data at ASCO 2026 ($290.58, 0.00)
CORRECTION: Adlai Nortye initiated at Oppenheimer with target of $32 ($11.00, 0.00)
Adlai Nortye initiated outperform at Oppenheimer ($11.00, 0.00)
Powered by FactSet Research Systems Inc.